Item 2.02 Results of Operations and Financial Condition.
On
The preliminary selected financial results included in the press release are
based upon estimates and information available as of the date of the press
release. Accordingly, undue reliance should not be placed on these preliminary
estimates. In addition, the Company has not yet completed its financial close
process for the quarter and year ended
Item 7.01 Regulation FD Disclosure.
The press release issued by the Company on
The Company has posted a presentation (the "Presentation") to its website at www.dynavax.com, in the "Events & Presentations" subsection of the "News & Events" tab. A copy of the Presentation is attached as Exhibit 99.2 to this current report and is incorporated herein by reference.
All of the information furnished in this Form 8-K, including the accompanying
Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information contained in this current report and in the
accompanying exhibit shall not be incorporated by reference into any filing with
the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is furnished herewith:
99.1 Press release dated
Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1
Shingles Topline Results". 99.2 Dynavax Investor Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source